Skip to main content
Figure 5 | BMC Surgery

Figure 5

From: Neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETS TNM-classification and immunohistochemical markers for risk stratification

Figure 5

Patient survival stratified for intratumoral E-cadherin and β-catenin expression. (A) There was no statistically significant survival difference between patients with low (N = 9), intermediate (N = 15) and high (N = 13) expression levels of E-cadherin (67 ± 21 versus 91 ± 16 versus 82 ± 16 months; P = 0.855). (B) No statistically significant survival differences were noted for patients with low (N = 12), intermediate (N = 13) and high (N = 12) expression levels of β-catenin (70 ± 18 versus 97 ± 16 versus 77 ± 16 months; P = 0.795).

Back to article page